Venetoclax Extension Study

[M19-388] An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial - Venetoclax Extension Study

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2051220047

Enrollment

550

Registered

2022-06-10

Start date

2022-07-06

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Myeloma

Interventions

Venetoclax

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: - Subject has been enrolled and dosed in an ongoing venetoclax study and continues to tolerate and derive benefit from the study drug. - Male subject agrees to refrain from sperm donation. - Female subjects must not be pregnant or breastfeeding.

Exclusion criteria

Exclusion criteria: - None

Design outcomes

Primary

Measure	Time frame
Adverse Events	—

Countries

Australia, Austria, Belgium, Canada, Denmark, France, Greece, Hong Kong, Ireland, Japan, Mexico, New Zealand, Poland, Portugal, Russian Federation, Spain, Sweden, Taiwan, Turkey, United Kingdom, United States

Contacts

Public ContactPatients and HCP Contact

AbbVie GK

AbbVie_JPN_info_clingov@abbvie.com+81-120-587-874

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026